Heartburn
Drug research and approvals for heartburn: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 10 studies of heartburn are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and the EU has 4 authorised medicines for it.
- Recruiting worldwide: 10
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 4
- A Clinical Trial to Evaluate the Effects of a Supplement on Gut HealthNCT07927907 · Not applicable · Peach Perfect · starts Feb 1, 2026
- Vinegar and HeartburnNCT07927296 · Not applicable · Arizona State University · starts Nov 16, 2026
- A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in…NCT07752407 · Phase 3 · Phathom Pharmaceuticals, Inc. · starts Sep 25, 2026
- New Topical tReatment Options for Symptomatic patiEnts With Nonerosive gastroesophageaL Reflux dIsease (The RELIEF…NCT07624383 · Not applicable · Cellmedis · starts May 28, 2026
- Study on Hydrotalcite for Relief of Acid Symptoms Due to Acid Rebound After Stopping Long-Term PPI TherapyNCT07291700 · Not reported · Bayer · starts Nov 18, 2025
- Heartburn, Gastroesophageal Reflux DiseaseNCT07268820 · Phase 4 · Incheon St.Mary's Hospital · starts Jul 7, 2025
- Evaluating the Impact of Various Dietary Nitrate Supplements on Oral HealthNCT06956612 · Not applicable · Shatha Alhulaefi · starts May 23, 2025
- A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their OffspringNCT06660342 · Not reported · Phathom Pharmaceuticals, Inc. · starts May 15, 2025
- A Study of Breath Testing for Small Intestinal Bacterial OvergrowthNCT05976165 · Not applicable · Mayo Clinic · starts Nov 17, 2023
Approved 11
- MetoclopramideDopamine D2 receptor antagonist
- FamotidineHistamine H2 receptor antagonist
- CimetidineHistamine H2 receptor antagonist
- NizatidineHistamine H2 receptor antagonist
- RanitidineHistamine H2 receptor antagonist
- OmeprazolePotassium-transporting ATPase inhibitor
- DexlansoprazolePotassium-transporting ATPase inhibitor
- LansoprazolePotassium-transporting ATPase inhibitor
- Bismuth subsalicylateCyclooxygenase inhibitor
- Aluminum hydroxideAntacid
- Calcium carbonate
How its trials ended
91 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 24 whose ending is known, 79% met their primary endpoint, 4% missed it and 17% stopped early.
- Completed, result not reported5156%
- Met its primary endpoint1921%
- Ongoing910%
- Status unknown78%
- Stopped: enrollment or feasibility22%
- Stopped: other or unclear22%
- Missed its primary endpoint11%
| Aug 26, 2013 | Nexium ControlEsomeprazole | Haleon Ireland Dungarvan Limited | EMA ↗ |
| Jun 12, 2009 | Somac ControlPantoprazole | Takeda GmbH | EMA ↗ |
| Jun 11, 2009 | Pantozol ControlPantoprazole | Takeda GmbH | EMA ↗ |
| Jun 11, 2009 | Controloc ControlPantoprazole | Takeda GmbH | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA